Study to Evaluate Multiple Doses in Patients With Nasal Polyposis
A Phase 2, Randomized, Double-blind, Placebo-controlled, Study to Evaluate Multiple Doses of AK001 in Patients With Moderate to Severe Nasal Polyposis
Sponsor: Allakos Inc.
A PHASE2 clinical study on Nasal Polyposis, this trial is completed. The trial is conducted by Allakos Inc. and has accumulated 15 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
15 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
▶ Show 10 earlier versions
-
Oct 2022 — Dec 2022 [monthly]
Completed PHASE2
-
Dec 2021 — Oct 2022 [monthly]
Completed PHASE2
-
Feb 2021 — Dec 2021 [monthly]
Completed PHASE2
-
Jan 2021 — Feb 2021 [monthly]
Completed PHASE2
-
Jan 2019 — Jan 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2019 [monthly]
Completed PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Aug 2017 — Mar 2018 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Feb 2017 — Aug 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Apr 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Allakos Inc.
For direct contact, visit the study record on ClinicalTrials.gov .